Actively Recruiting
APIXABAN App Study
Led by Dong-Ju Choi · Updated on 2025-04-06
40
Participants Needed
1
Research Sites
43 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this clinical trial is to evaluate whether the medication reminder app and video call can improve medication adherence to apixaban in patients with AF and comorbidities. Patients with AF and comorbid heart disease taking apixaban who meet the inclusion criteria will be randomised 1:1 to a treatment arm using a medication reminder app and bi-weekly video education and a control arm using the medication reminder app alone to compare medication adherence. Patients in both groups will use the medication app, but only the treatment group will receive additional education and feedback via video call every two weeks to reinforce the use of the medication app and medication reminders with video education. The study aims to assess the change in adherence between the two groups at week 8.
CONDITIONS
Official Title
APIXABAN App Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 19 years or older with a diagnosis of atrial fibrillation (AF)
- Presence of at least one cardiovascular or metabolic comorbidity: heart failure, hypertension, coronary artery disease, peripheral arterial disease, diabetes mellitus, stroke, or other cardiac diseases requiring treatment
- Currently taking or planning to initiate oral anticoagulation therapy with apixaban
- Able to use a smartphone with an Android operating system
- Provided written informed consent after being informed about the study purpose, procedures, and risks
You will not qualify if you...
- Creatinine clearance (CCr) less than 15 mL/min
- Moderate to severe mitral stenosis
- History of mitral valve repair or replacement
- Clinically significant history of alcohol or substance abuse
- Legally or psychologically unsuitable for participation as determined by the investigator
- Participation in another clinical trial involving investigational drugs within 4 weeks prior to screening
- Declines or unwilling to provide informed consent for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Bundang Hospital
Seongnam, Gyeonggido, South Korea, 13620
Actively Recruiting
Research Team
M
Minjae Yoon, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here